SCHEMBL1338652

SCHEMBL1338652

Cn1c(=O)c(-c2ccc(F)cc2Cl)cc2c3ccccc3n(C)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.47
▸ TP53 P04637 1/20 0.45
▸ HSD11B1 P28845 2/20 0.44
▸ THRB P10828 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ RIPK2 O43353 1/20 0.39
▸ NOD2 Q9HC29 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ GRM4 Q14833 1/20 0.38
▸ MAPK14 Q16539 2/20 0.38
▸ CDC25A P30304 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338090 0.87 KDM4E (0.52) TP53HSD11B1KDM4EALDH1A1HPGD
SCHEMBL1337357 0.83 ALDH1A1 (0.50) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1337225 0.82 HPGD (0.42) ATMTP53HSD11B1KDM4EALDH1A1
SCHEMBL1336997 0.82 MAPK14 (0.49) ATMKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1338634 0.78 PTPN1 (0.36) ATMTP53HSD11B1THRBBRD4
SCHEMBL1337392 0.76 HSD17B10 (0.46) THRBKDM4EALDH1A1HPGDGAA
SCHEMBL1338982 0.75 CLK1 (0.36) HSD11B1THRBRIPK2NOD2MAPK14
SCHEMBL2382190 0.72 F2RL3 (0.46) TP53HSD11B1KDM4EALDH1A1HPGD
SCHEMBL1339317 0.72 KDM4E (0.42) TP53HSD11B1KDM4EALDH1A1HPGD
SCHEMBL1339132 0.71 HSD17B10 (0.46) KDM4EALDH1A1HPGDGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ATM 2693/4885TP53 1413/4885HSD11B1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback